Silence Therapeutics (SLN) Return on Sales (2024 - 2026)

Silence Therapeutics has disclosed Return on Sales across 3 years of filings, most recently posting 0.35% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.35%, up 165.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.93% (down 91.0% YoY), and the FY2025 annual result was 1.6%, down 159.0% from the prior year.
• Return on Sales came in at 0.35% for Q1 2026 at Silence Therapeutics, up from 3.78% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q4 2024 to a low of 3.78% in Q4 2025.
• The 3-year median for Return on Sales is 0.35% (2026), against an average of 1.04%.
• Across the five-year window, Return on Sales slumped 378 bps in 2025 and surged 165 bps in 2026, its largest moves.
• Silence Therapeutics' Return on Sales stood at 0.0% in 2024, then sank by 77830 bps to 3.78% in 2025, then soared by 91 bps to 0.35% in 2026.
• The last three Return on Sales figures came in at 0.35% (Q1 2026), 3.78% (Q4 2025), and 1.32% (Q3 2025), per Business Quant data.